ホーム › 腎臓がん（腎細胞がん） › メリーランド州
メリーランド州における腎臓がん（腎細胞がん）の臨床試験
メリーランド州内の拠点で、腎臓がん（腎細胞がん）に関する17件の研究が参加者を募集しています。
メリーランド州内の都市
公式研究テキスト（英語）
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
- Research Site, Baltimore
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/05更新 · NCT05536141Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
- National Institutes of Health Clinical Center, Bethesda
被験者募集中第2相
18歳〜120歳 · 全性別 · 2026/10/02更新 · NCT05155033Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Medical Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
- 他10件
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #14, Baltimore
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/01更新 · NCT05176483Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- National Institutes of Health Clinical Center, Bethesda
- FMH James M Stockman Cancer Institute, Frederick
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/30更新 · NCT03866382Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
- NCI - Center for Cancer Research, Bethesda
被験者募集中第2相
12歳以上 · 全性別 · 2026/09/29更新 · NCT04981509A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
- Johns Hopkins Hospital, Baltimore
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/23更新 · NCT07293351Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
- University of Maryland/Greenebaum Cancer Center, Baltimore
- UPMC Western Maryland, Cumberland
- UM Baltimore Washington Medical Center/Tate Cancer Center, Glen Burnie
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/02更新 · NCT06661720Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders
- National Institutes of Health Clinical Center, Bethesda
被験者募集中観察研究健康なボランティア歓迎
2歳以上 · 全性別 · 2026/08/24更新 · NCT00001238Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- National Institutes of Health Clinical Center, Bethesda
被験者募集中第1/2相
18歳〜72歳 · 全性別 · 2026/08/13更新 · NCT02830724A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
- National Institutes of Health Clinical Center, Bethesda
被験者募集中観察研究
18歳以上 · 全性別 · 2026/08/10更新 · NCT04923178A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
- Greater Baltimore Medical Center ( Site 0145), Baltimore
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/03更新 · NCT07227402Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)
- National Institutes of Health Clinical Center, Bethesda
被験者募集中第1/2相
18歳〜100歳 · 全性別 · 2026/07/29更新 · NCT05665361Study of 111In-XYIMSR-01 SPECT/CT in Patients With Metastatic Clear Cell Renal Cell
- Johns Hopkins University, Baltimore
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/21更新 · NCT07062549A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)
- Johns Hopkins University (Data Collection Only), Baltimore
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/06/24更新 · NCT06835972Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
- Johns Hopkins Hospital /ID# 254056, Baltimore
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/04更新 · NCT04777994Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
被験者募集中第2相
18歳〜120歳 · 全性別 · 2026/03/30更新 · NCT03786796ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。